What are the adverse reactions of trifluridine and tipiracil (Lansifer)?

The combination of trifluridine and tipiracil (Lonsurf) is used alone or in combination with bevacizumab to treat the colon (large intestine) or rectum of people who have been treated with other chemotherapy drugs or who cannot be treated with these chemotherapy drugs. Cancer. The combination of trifluridine and tipiracil is also used to treat certain types of stomach cancer or cancer located at the junction of the stomach and esophagus (the tube between the throat and stomach) that has spread to other parts of the body in people who have received at least two other types of chemotherapy.

When trifluridine is used as monotherapy, the most common adverse reactions include hematological abnormalities such as neutropenia, anemia, and thrombocytopenia. These reactions may be related to the inhibitory effect of the drug on bone marrow hematopoiesis. In addition, patients may also experience non-specific symptoms such as fatigue, nausea, loss of appetite, diarrhea, vomiting, abdominal pain and fever. These adverse reactions may affect patients' daily quality of life and treatment compliance, and therefore require prompt attention and proper handling.

When trifluridine tipiracil is used in combination with bevacizumab, in addition to the common adverse reactions mentioned above, some adverse reactions related to the combination may also occur. For example, liver function indicators such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) may be elevated, which may be related to drug damage to the liver. In addition, abnormalities in biochemical indicators such as elevated alkaline phosphatase and reduced serum sodium may also occur. At the same time, gastrointestinal symptoms such as diarrhea, abdominal pain, and loss of appetite may also worsen. These adverse reactions may require adjustments to the treatment plan or corresponding supportive care measures to be alleviated.